Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, and Cutaneous Melanoma Detection and Management.
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes
Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts
Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development.
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma